)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Microba Life Sciences (MAP) investor relations material
Microba Life Sciences Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary23 Jul, 2025
Executive summary
Achieved record core test sales and 88% year-on-year growth, with strong clinical adoption in Australia and the UK; transitioned focus to core testing products and discontinued legacy lines.
FY25 revenue reached $15.67 million, up 30% year-on-year, with both Australia and the UK achieving regional break-even milestones.
Released landmark clinical studies showing actionable results in over 70% of cases and significant detection of undiagnosed pathogens, supporting product adoption.
All R&D investment in therapeutics ceased; focus shifted to partnering, with sector deal catalysts expected in late CY2025.
Completed a $14.5m capital raise, ensuring a solid cash position to support growth and break-even targets in FY26.
Financial highlights
FY25 revenue reached $15.67m, up 30% year-on-year, in line with guidance, despite legacy product phase-out.
Q4 FY25 revenue was $4.2m, up 22–23% sequentially, but down 13.5% year-on-year due to legacy product discontinuation.
Cash and equivalents at 30 June 2025 were $11.7m, with an additional $8.45m to settle in August.
In vivo branded supplement sales grew 12% year-on-year, while distributed supplement sales declined.
Operating cash outflows for Q4 totaled $5.56m, driven by manufacturing, R&D, and staff costs.
Outlook and guidance
FY26 guidance targets over 24,000 core tests and regional break-even milestones in Australia and the UK, with 100% year-on-year core test volume growth expected.
Anticipates similar growth profile in FY26 as FY25, with step-ups each quarter aligned to clinician adoption and product releases.
Group EBITDA break-even contingent on continued clinical adoption and sufficient capital for expansion.
Entry into US and Europe planned, with initial market penetration in one geography per region.
Operating cash outflows planned to decrease in FY26, aligned with strategic focus.
Assess sustainability of growth in AU/UK.
Elaborate on the therapeutics partnering timeline.
Explain the strategy for supplement sales growth.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Microba Life Sciences earnings date
Q1 202627 Oct, 2025
Next Microba Life Sciences earnings date
Q1 202627 Oct, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Microba Life Sciences Limited is a biotechnology company specializing in microbiome analysis and therapeutics. The company provides advanced gut microbiome testing services using metagenomic sequencing technology to offer insights into human health. Microba also conducts research and development to discover and develop microbiome-based therapeutics targeting conditions such as inflammatory and metabolic diseases. The company is headquartered in Brisbane, Australia, and its shares are listed on the ASX.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage